Business Description
Marker Therapeutics Inc
NAICS : 325414
SIC : 2834
ISIN : US57055L2060
Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.84 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 34.2 | |||||
3-Year EPS without NRI Growth Rate | 36.1 | |||||
3-Year FCF Growth Rate | 33.1 | |||||
3-Year Book Growth Rate | -33.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 10 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 62 | |||||
9-Day RSI | 64.49 | |||||
14-Day RSI | 62.68 | |||||
6-1 Month Momentum % | -36.96 | |||||
12-1 Month Momentum % | 3.06 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.12 | |||||
Quick Ratio | 6.12 | |||||
Cash Ratio | 4.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.6 | |||||
Shareholder Yield % | -0.89 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -36.53 | |||||
ROA % | -28.14 | |||||
ROIC % | -337.95 | |||||
ROC (Joel Greenblatt) % | -73.62 | |||||
ROCE % | -76.03 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.75 | |||||
Price-to-Tangible-Book | 3.77 | |||||
EV-to-EBIT | -2.04 | |||||
EV-to-EBITDA | -2.04 | |||||
EV-to-Forward-Revenue | 0.56 | |||||
EV-to-FCF | -1.82 | |||||
Price-to-Net-Current-Asset-Value | 3.77 | |||||
Price-to-Net-Cash | 4.94 | |||||
Earnings Yield (Greenblatt) % | -49.02 | |||||
FCF Yield % | -32.46 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Marker Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.592 | ||
Beta | 0.51 | ||
Volatility % | 55.74 | ||
14-Day RSI | 62.68 | ||
14-Day ATR (€) | 0.165421 | ||
20-Day SMA (€) | 4.11 | ||
12-1 Month Momentum % | 3.06 | ||
52-Week Range (€) | 2.814 - 4.9 | ||
Shares Outstanding (Mil) | 8.92 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Marker Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Marker Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Marker Therapeutics Inc Frequently Asked Questions
What is Marker Therapeutics Inc(FRA:GX1)'s stock price today?
The current price of FRA:GX1 is €4.64. The 52 week high of FRA:GX1 is €4.90 and 52 week low is €2.81.
When is next earnings date of Marker Therapeutics Inc(FRA:GX1)?
The next earnings date of Marker Therapeutics Inc(FRA:GX1) is 2024-08-14 Est..
Does Marker Therapeutics Inc(FRA:GX1) pay dividends? If so, how much?
Marker Therapeutics Inc(FRA:GX1) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |